E-viri
Recenzirano
Odprti dostop
-
Rögnvaldsson, Sæmundur; Love, Thorvardur Jon; Thorsteinsdottir, Sigrun; Reed, Elín Ruth; Óskarsson, Jón Þórir; Pétursdóttir, Íris; Sigurðardóttir, Guðrún Ásta; Viðarsson, Brynjar; Önundarson, Páll Torfi; Agnarsson, Bjarni A; Sigurðardóttir, Margrét; Þorsteinsdóttir, Ingunn; Ólafsson, Ísleifur; Þórðardóttir, Ásdís Rósa; Eyþórsson, Elías; Jónsson, Ásbjörn; Björnsson, Andri S; Gunnarsson, Gunnar Þór; Pálsson, Runólfur; Indriðason, Ólafur Skúli; Gíslason, Gauti Kjartan; Ólafsson, Andri; Hákonardóttir, Guðlaug Katrín; Brinkhuis, Manje; Halldórsdóttir, Sara Lovísa; Ásgeirsdóttir, Tinna Laufey; Steingrímsdóttir, Hlíf; Danielsen, Ragnar; Dröfn Wessman, Inga; Kampanis, Petros; Hultcrantz, Malin; Durie, Brian G M; Harding, Stephen; Landgren, Ola; Kristinsson, Sigurður Yngvi
Blood cancer journal, 05/2021, Letnik: 11, Številka: 5Journal Article
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.